Pluss unveils Celsure XL VIP pallets
A game changing solution for the pharmaceutical industry
A game changing solution for the pharmaceutical industry
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
New leadership team announced at NATHEALTH Annual General Meeting 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Subscribe To Our Newsletter & Stay Updated